click below
click below
Normal Size Small Size show me how
Pharm Ch38
Cancer - Signal Transduction
| Question | Answer |
|---|---|
| MOA of Gefitinib, Erlotinib, Cetuximab, Trastuzumab | EGFR Antagonists |
| Reversible inhibitor of tyrosine kinase, PO; Tx: NSCLCs | Gefitinib |
| 2nd or 3rd line Tx: NSCLC, colon, pancreatic, H&N cancer, glioblastoma | Erlotinib |
| binds EGFR (ErbB1), Tx: H&N cancer, ADR: skin rash, diarrhea | Cetuximab |
| binds ErbB2 (HER-2) Tx: breast cancer, ADR: cardiotoxicity | Trastuzumab |
| MOA of Imatinib mesylate | inhibits ABL kinase (targeted therapeutic) |
| Tx: CML (BCR-ABL), GIST (C-KIT), systemic mastocytosis, idiopathic hypereosinophilic syndrome (PDGFRA), ADR: edema, N/D, cramps, rash | Imatinib mesylate |
| MOA of Sorafenib | B-RAF inhibitor (MAP Kinase Pathway Inhibition) |
| Tx: melanoma, RCC | Sorafenib |
| MOA of Rapamycin (Sirolimus) | binds to FKBP12 (mTOR Inhibitor) which causes immunosuppression, promotes cell cycle inhibition, apoptosis and angiogenesis inhibition |
| MOA of Bortezomib | Proteasome Inhibitor: targets N-terminal threonine residue of 20S subunit |
| Tx: refractory multiple myeloma, ADR: neuropathy, thrombocytopenia, neutropenia | Bortezomib |
| MOA of Bevacizumab | Anti-VEGF-A Antibody |
| Tx: refractory RCC, ADR: proteinuria, HTN, thrombosis, bleeding | Bevacizumab |
| MOA of Sunitinib | inhibits VEGFR-1, 2, PDGFR |
| synthetic glutamic acid derivative (IMiD), inhibits TNF-a, bFGF Tx: ENL, multiple myeloma, ADR: teratogenic, phocomelia, thrombosis, neuropathy | Thalidomide |
| synthetic second-gen IMiD, Tx: refractory multiple myeloma, MDS (del 5q), ADRs: myelosuppression, thrombocytopenia | Lenalidomide |
| anti-CD20 IgG1, Tx: B-cell NHL, ADRs: immunosuppression, hypersensitivity | Rituximab |